Group items tagged

This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications from institutions/organizations that propose to advance our knowledge in the area of the physics and mechanics of embryonic development. Applicants must propose hypothesis-driven developmental research with the prospect of gaining new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders. Investigators are encouraged to explore approaches and concepts new to the area of developmental tissue mechanics, and use newly developed techniques superior to the ones currently used in the field. It should be noted that applications using the NIH R01 grant mechanism will require sufficient preliminary data to substantiate the validity of the proposed research and feasibility of new technologies or tools.

The objective of FDA's Orphan Products Natural History Grants Program is to support studies that characterize the natural history of rare diseases/conditions, identify genotypic and phenotypic subpopulations, and develop and/or validate clinical outcome measures, biomarkers and/or companion diagnostics. The ultimate goal of these natural history studies is to support clinical development of products for use in serious rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA provides grants for natural history studies that will either assist or substantially contribute to market approval of these products. Applicants must include in the application's Background and Significance section documentation to support that the estimated prevalence of the orphan disease or condition in the US is less than 200,000 (or in the case of a vaccine or diagnostic, information to support that the product will be administered to fewer than 200,000 people in the US per year), and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.  Additional information may be required upon request, for example, regarding population estimate and rationale.

The Agency for Healthcare Research and Quality (AHRQ) is interested in funding a diverse set of projects that develop, test and evaluate various simulation approaches for the purpose of improving the safe delivery of health care. Simulation in health care serves multiple purposes. As a training technique, it exposes individuals and teams to realistic clinical challenges through the use of mannequins, task trainers, virtual reality, standardized patients or other forms, and allows participants to experience in real-time the consequences of their decisions and actions. The principal advantage of simulation is that it provides a safe environment for health care practitioners to acquire valuable experience without putting patients at risk. Simulation also can be used as a test-bed to improve clinical processes and to identify failure modes or other areas of concern in new procedures and technologies that might otherwise be unanticipated and serve as threats to patient safety. Yet another application of simulation focuses on the establishment of valid and reliable measures of clinical performance competency and their potential use for credentialing and certification purposes. The foremost aim of the announcement is to advance patient safety. Keeping this aim in mind, applications that address a variety of simulation techniques, clinical settings, provider groups, priority populations, and patient conditions are welcomed.

he U.S. Congress provides funds to CDC for programmatic support and procurement of vaccines critical to the success of the global initiatives for polio eradication and measles mortality reduction. The purpose of the program is to support the US Government-endorsed Global Polio Eradication Initiative, Global Measles Initiative, and the Global Immunization Vision and Strategy (GIVS) of which UNICEF is a key partner. Other key partners include CDC, World Health Organization (WHO), the Pan American Health Organization (PAHO), Rotary International, American Red Cross, and the UN Foundation. UNICEF, in conjunction with CDC, will provide programmatic assistance and vaccines for supplemental immunization activities (SIAs) in priority countries as well as strengthening of routine immunization delivery systems and capacities in developing countries to achieve globally agreed goals for disease eradication, elimination and reduction. Additionally this agreement may be used to support activities to address other global health priorities in line with CDC goals. Under this agreement, UNICEF will collaborate with CDC, World Health Organization (WHO), Rotary International, other partner agencies and national governments, for implementation of strategies to achieve the globally agreed goals of polio eradication, measles mortality reduction and elimination, and control of other vaccine preventable diseases (VPD), including identification and prioritization of country vaccine and programmatic assistance needs.

he U.S. Congress provides funds to CDC for programmatic support and procurement of vaccines critical to the success of the global initiatives for polio eradication and measles mortality reduction. The purpose of the program is to support the US Government-endorsed Global Polio Eradication Initiative, Global Measles Initiative, and the Global Immunization Vision and Strategy (GIVS) of which UNICEF is a key partner. Other key partners include CDC, World Health Organization (WHO), the Pan American Health Organization (PAHO), Rotary International, American Red Cross, and the UN Foundation. UNICEF, in conjunction with CDC, will provide programmatic assistance and vaccines for supplemental immunization activities (SIAs) in priority countries as well as strengthening of routine immunization delivery systems and capacities in developing countries to achieve globally agreed goals for disease eradication, elimination and reduction. Additionally this agreement may be used to support activities to address other global health priorities in line with CDC goals. Under this agreement, UNICEF will collaborate with CDC, World Health Organization (WHO), Rotary International, other partner agencies and national governments, for implementation of strategies to achieve the globally agreed goals of polio eradication, measles mortality reduction and elimination, and control of other vaccine preventable diseases (VPD), including identification and prioritization of country vaccine and programmatic assistance needs. 

The purpose of this BD2K Funding Opportunity Announcement (FOA) is to support the development, improvement and implementation of tools and approaches that increase the efficiency and effectiveness of digital curation processes used to characterize and describe the digital data used in or resulting from biomedical research.

The purpose of this BD2K Funding Opportunity Announcement (FOA) is to support the development, improvement and implementation of tools and approaches that increase the efficiency and effectiveness of digital curation processes used to characterize and describe the digital data used in or resulting from biomedical research.

This Funding Opportunity Announcement (FOA) is intended to address the problem of misidentified cell lines. Many advances in biomedical science have arisen from studies of cultured cell lines, which are widely used for basic research on cell function, as models for disease, and for drug screening.  In most of this research, correct identification of the cell lines used is necessary to replicate experiments.  In addition, in a majority of the projects the cell lines used were chosen because they are predicated to recapitulate biologically important features of the tissue and/or tumor of origin, for example, driver mutations, expression patterns, and functional correlates of the differentiated state of the original tissue. Cell line origins are documented by chain of custody (a continuous chronological record documenting their source, transfer, analysis, and disposition).  However, cell lines in culture are prone to contamination by foreign cells, which may rapidly displace the original cells.  The identity of cultured cells should be routinely verified, but a majority of laboratories do not monitor the identity of their cell lines, and many cell lines are misidentified.  Analyses of cells submitted to major repositories such as the ATCC (American Type Culture Collection) and the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) have found that 15-40% of cell lines submitted by investigators are misidentified, i.e., they have a tissue or species of origin that differs from the one reported.  Similar frequencies of misidentification have been reported by research laboratories that have examined cell line collections.

The purpose of IFER's Fellowship Program is to provide financial incentives to graduate students in science that encourage them at the earliest stages of their career to integrate innovation and discovery with ethics and respect for animals. Fellowships are awarded to those candidates whose program of study shows the greatest potential to replace the use of animals in science. Graduate Fellowships to develop alternatives to the use of animals in research, testing and education are open to students enrolled in Master's and Ph.D. programs in the sciences, and human or veterinary medicine. Fellowships will also be considered for graduate students in other fields, such as education, psychology, humanities, journalism, and the law, for projects that show promise to increase public awareness or to promote changes in the legal system or public policy regarding the use of animals in research, testing, and education.

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to develop novel in vivo imaging technologies using molecular probes that target pathways or cells involved in the pathobiology of pulmonary diseases. The long-term goal of this program is to develop novel molecular imaging entities and approaches that facilitate early detection and diagnosis of lung disease, enable noninvasive monitoring of lung disease progression and prognosis, and accelerate progress of cell-specific drug delivery and therapies.The previous FOA (RFA-HL-12-036 - Phase 1) supported projects to develop and validate innovative novel imaging agents and approaches that included target selection, probe development and production, and initial characterization of the probe. Phase 2 of this initiative will support studies that advance translation of identified probes and associated imaging approaches from animal models into applicability for human lung diseases. Phase 2 studies must include work performed in vivo using appropriate animal models of lung diseaseand studies using human tissues and/or cells. Applications proposing Investigational New Drug (IND)-enabling studies of novel probes and imaging approaches are encouraged. Applicants are not required to have been funded in Phase 1 (RFA-HL-12-036) in order to submit applications for Phase 2.

The PCC has supported world-class research since 2009, spending more than $8.0 M to support novel science. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

The American Fund for Alternatives to Animal Research and the New England Anti-Vivisection Society are offering a $40,000, one-year postdoctoral fellowship grant (with possible renewal) to a woman interested in using alternatives to animal methods in the investigation of women's health or sex differences. The award is available to female postdoctoral scientists researching women's health or sex differences whose research involves the development, validation, or use of non-animal alternatives. Applicants must be interested in using or promoting non-animal alternatives in research.

The Macrosystems Biology and NEON-Enabled Science (MSB-NES): Research on Biological Systems at Regional to Continental Scales program will support quantitative, interdisciplinary, systems-oriented research on biosphere processes and their complex interactions with climate, land use, and invasive species at regional to continental scales as well as training activities to enable groups to conduct Macrosystems Biology and NEON-Enabled Science research. Proposers are encouraged to use NEON resources, and proposals for substantive and innovative NEON-enabled research will be prioritized for funding. Substantive NEON-enabled projects rely on data and/or samples collected by NEON, co-locate research activities at NEON sites, and/or develop tools that will explicitly enhance the processing, use, and/or analysis of NEON data or collections within the context of Macrosystems Biology research questions.

Tissue This FOA will provide funding for Investigators to create and test devices that can model the mechanisms or effects of nociception/pain-relevant signaling, addiction, or opioid use disorders (OUDs), using human tissues in in vitro microphysiological systems (MPS). Tissue chips, or microphysiological systems, are useful and promising in vitro human-based screening platforms because they closely mimic in vivo human physiology. Tissue chips have been shown to be capable of modeling normal and diseased physiology that faithfully recapitulates responses to stressors, treatments and other perturbations. This FOA is part of the of the NIHs Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative.

The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

The purpose of this Funding Opportunity Announcement is to support research activities that will advance NIAIDs mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA uses the R21 grant mechanism, while the companion FOA, PA-XX-xxx , uses the R01 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or planning longer-term studies may wish to apply using the R01 mechanism.

This Funding Opportunity Announcement (FOA) intends to accelerate the integration and use of scalable technologies and tools to enhance and reinvigorate brain cell census research, including the development of technology platforms and/or resources that will enable a swift and comprehensive survey of brain cell types and circuits. Of particular interest are those that will (a) improve technology and resource platforms to remove limitations and bottlenecks in the current pipeline of brain cell census data generation; (b) integrate experimental and computational methods to enhance capabilities of cell census data generation and analysis and to reduce barriers to hypothesis-driven research; (c) generate a substantial amount of spatiotemporal cell census data and/or resources to demonstrate the utility of the improved technology and resource platforms; and (d) conduct comparative studies by using proper criteria to evaluate and benchmark quality of biospecimen, performance of cell census tools/technologies, and effectiveness of computational approaches. The projects funded under this FOA will align with the overarching goals of the BRAIN Initiative Cell Census Network (BICCN) and are expected to generate a substantial amount of cell census data using the proposed technologies or via collaboration with the BICCN.

The Agency for Healthcare Research and Quality (AHRQ) seeks applications to disseminate patient-centered outcomes research (PCOR) findings directly to primary care practices and support practices in implementing PCOR clinical and organizational findings. Applicants must propose a comprehensive plan that uses evidence-based strategies designed to improve the delivery of patient-centered approaches to identifying and managing unhealthy alcohol use among adults, including screening and brief intervention (SBI) and medication assisted therapy (MAT).

The Michael J. Fox Foundation will award one- to three-year grants to develop imaging markers for use in disease-modifying clinical trials. Imaging is a powerful tool that can be used to visualize the structure and function of the brain in living subjects. While a variety of imaging techniques are available, including positron emission tomography (PET), single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI), none have been demonstrated to be a sensitive, specific and reliable biomarker test for the presence and progression of PD. Applications must focus on developing robust and precise imaging markers. Priority targets for this program are alpha-synuclein and neuroinflammation, but applications may focus on other promising therapeutic targets. Imaging modalities can include PET, SPECT and MRI. Projects should aim to develop novel imaging biomarkers as opposed to prospectively collecting data using existing technologies. Prospective data collection is appropriate only if a novel imaging technique or tracer is being tested. Novel data analysis techniques may be proposed but should utilize existing data sets. Examples of projects that are appropriate for this program include development of novel PET or SPECT tracers, early validation of new tracers, and development and validation of novel MRI techniques.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. This FOA is intended to support research education activities that enhance the knowledge of substance use and substance use disorder research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two. This mechanism may not be used to support non-research-related clinical training.

The Home Depot Foundation is accepting applications from nonprofit organizations using volunteers to address the physical needs of their communities. Through its Community Impact Grants program, the foundation will award grants of up to $5,000 (in the form of Home Depot gift cards that can be used to purchase tools, materials, and services) for projects aimed at repairing, modifying, weatherizing, or otherwise improving low-income and/or transitional housing or community facilities. Priority will be given to programs that use volunteers to serve veterans with home-improvement needs. Only IRS-registered 501(c)(3) nonprofit organizations and tax-exempt public service agencies (e.g., police/fire departments) in the United States are eligible to apply. In addition, grants must support work completed by community volunteers in the U.S., and projects must be completed within six months following notification that the grant has been awarded.

There are 5.4 million individuals who self-identify as American Indian/Alaska Native (AI/AN) in the US, and there are 567 federally registered tribes. While characterized by many strengths and resiliencies, as a whole, AI/AN populations experience significant disparities compared to the general population across a range of health conditions and outcomes, including infant mortality, alcohol-related mortality, substance abuse, unintentional injury, homicide, suicide, depression, post-traumatic stress disorder, obesity, chronic kidney disease, asthma, diabetes, cardiovascular disease, selected cancers, and other chronic diseases. Premature death rates, while decreasing in other US racial/ethnic minority populations over the past 15 years, are increasing among AI/AN populations. However, the examination of data on AI/AN populations in aggregate may obscure the significant heterogeneity within the AI/AN population due to tribal affiliation, geographic region, and other factors. For example, gastric cancers affect AI/AN populations in different parts of the country at different rates ranging from 6.1/100,00 in the Eastern US to 24.5/100,000 in Alaska. At the same time, national survey and epidemiological studies often do not report data on AI/AN populations because the numbers are too small or AI/AN individuals are folded into the highly heterogeneous "Other" category, thus not available to interpret any health outcomes specific for AI/AN populations. For these reasons, there is a critical need to build a more comprehensive evidence base regarding the health of AI/AN populations.